Ray Dalio's NVO Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 0 shares of Novo Nordisk A/S (NVO) worth $0, representing 0.00% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in NVO, representing a fresh investment thesis on this company. Largest reduction occurred in Q4 2025, reducing 138,947 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -138,947 | Sold Out | 0 | $0.00 |
| Q3 2025 | +138,947 | New Buy | 138,947 | $55.49 |
Ray Dalio's Novo Nordisk A/S Investment FAQs
Ray Dalio first purchased Novo Nordisk A/S (NVO) in Q3 2025, acquiring 138,947 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Novo Nordisk A/S (NVO) for 2 quarters since Q3 2025.
Ray Dalio's largest addition to Novo Nordisk A/S (NVO) was in Q3 2025, adding 138,947 shares worth $7.71 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 0 shares of Novo Nordisk A/S (NVO), valued at approximately $0.
As of the Q4 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Novo Nordisk A/S (NVO) was 138,947 shares, as reported at the end of Q3 2025.